Actively Recruiting
A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe
Led by Ahn-Gook Pharmaceuticals Co.,Ltd · Updated on 2025-08-07
4500
Participants Needed
1
Research Sites
178 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of this study is to evaluate the effectiveness and safety of Pitavastatin/Ezetimibe FDC in patients with hypercholesterolemia.
CONDITIONS
Official Title
A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 19 years or older
- Diagnosed with hypercholesterolemia and stably treated with atorvastatin or rosuvastatin monotherapy for at least 3 months
- Clinical laboratory test results related to cholesterol and liver/kidney function available within 12 months before switching treatment
- Provided written informed consent to participate
You will not qualify if you...
- Known hypersensitivity to any component of the investigational product
- Active liver disease or unexplained persistent elevation of liver enzymes
- Severe liver impairment, biliary obstruction, or cholestasis
- Currently receiving cyclosporine treatment
- Diagnosed with myopathy
- Pregnant or breastfeeding women, or women who may be pregnant
- Genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- Deemed unsuitable for study participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yongin Severance Hospital
Yongin-si, South Korea
Actively Recruiting
Research Team
H
Hyunji Kim
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here